ACST · Acasti Pharma Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $100.00M | - | - | - |
| Cost of Revenue | - | - | - | $0 | $76.0K | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $9.51M | $4.68M | $9.97M | $5.56M | $4.17M | $15.97M |
| SG&A | $7.17M | $6.43M | $7.61M | $9.26M | $5.52M | $5.80M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $7.0K | $11.0K | $124.0K | $0 | $143.0K | $410.0K |
| Operating Income | ($16.68M) | ($12.85M) | ($52.16M) | ($15.59M) | ($16.42M) | ($24.44M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | ($3.20M) | ($1.83M) | ($9.54M) | $0 | - | $0 |
| Net Income | ($9.57M) | ($12.85M) | ($42.43M) | ($9.82M) | ($19.68M) | ($25.51M) |
| EPS - Basic | ($0.79) | ($1.35) | ($0.27) | - | - | - |
| EPS - Diluted | ($0.79) | ($1.35) | ($0.27) | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.13M | $23.00M | $27.88M | $30.34M | $50.94M | $16.87M |
| Accounts Receivable | - | $722.0K | $802.0K | $548.0K | $530.0K | $1.19M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $601.0K | $1.01M | $1.24M | $1.68M | $115.0K | $1.71M |
| Current Assets | $22.71M | $24.01M | $29.29M | $45.53M | $62.37M | $27.97M |
| Total Assets | $71.99M | $73.30M | $79.12M | $128.62M | $62.46M | $36.90M |
| Current Liabilities | $1.93M | $1.68M | $3.41M | $3.26M | $1.58M | $13.67M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $5.38M | $11.56M | $11.17M | $20.35M | $6.80M | $9.86M |
| Stockholders' Equity | $66.61M | $61.74M | $67.95M | $108.27M | $55.66M | $7.19M |
| Retained Earnings | ($220.69M) | ($211.12M) | ($198.27M) | ($155.84M) | ($146.02M) | ($100.83M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($14.90M) | ($12.33M) | ($15.91M) | ($17.23M) | ($22.95M) | - |
| Investing Cash Flow | $0 | $104.0K | $13.15M | ($3.52M) | $8.14M | - |
| Financing Cash Flow | $14.03M | $7.36M | $304.0K | $0 | $13.18M | - |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | -52.2% | - | - | - |
| EBITDA margin | - | - | -52.0% | - | - | - |
| Net margin | - | - | -42.4% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | 10.0% | - | - | - |
| SG&A / Revenue | - | - | 7.6% | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -13.3% | -17.5% | -53.6% | -7.6% | -31.5% | -69.1% |
| Return on equity | -14.4% | -20.8% | -62.4% | -9.1% | -35.4% | -354.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 11.77 | 14.26 | 8.59 | 13.97 | 39.50 | 2.05 |
| Quick ratio | 11.77 | 14.26 | 8.59 | 13.97 | 39.50 | 2.05 |
| Cash ratio | 11.47 | 13.66 | 8.17 | 9.31 | 32.26 | 1.23 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.08 | 1.19 | 1.16 | 1.19 | 1.12 | 5.13 |
| Liabilities / Assets | 0.07 | 0.16 | 0.14 | 0.16 | 0.11 | 0.27 |
| Efficiency | ||||||
| Asset turnover | - | - | 1.26 | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | 3d | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | 552d | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -29.8% | 75.4% | -234.6% | 5.1% | 32.8% | - |
| Net income growth (YoY) | 25.6% | 69.7% | -332.1% | 50.1% | 22.9% | - |
| EPS growth (YoY) | 41.5% | -400.0% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 7.9% | -9.1% | -37.2% | 94.5% | 673.8% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Acasti Pharma Inc. against the 5 most active filers in the same SIC group.